Akorn, Inc. (NASDAQ:AKRX) Director Brian Tambi sold 15,100 shares of Akorn stock in a transaction dated Tuesday, November 21st. The stock was sold at an average price of $33.35, for a total value of $503,585.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Akorn, Inc. (NASDAQ:AKRX) traded up $0.07 during trading on Wednesday, reaching $32.37. The company’s stock had a trading volume of 3,091,750 shares, compared to its average volume of 2,785,376. The company has a debt-to-equity ratio of 0.92, a quick ratio of 3.17 and a current ratio of 4.16. The company has a market cap of $4,177.36, a PE ratio of 20.75, a price-to-earnings-growth ratio of 1.99 and a beta of 1.33. Akorn, Inc. has a fifty-two week low of $17.61 and a fifty-two week high of $34.00.

ILLEGAL ACTIVITY WARNING: This article was posted by American Banking News and is owned by of American Banking News. If you are reading this article on another site, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/11/22/akorn-inc-akrx-director-brian-tambi-sells-15100-shares.html.

Several research analysts have recently commented on AKRX shares. TheStreet downgraded Akorn from a “b-” rating to a “c” rating in a report on Tuesday, August 1st. Jefferies Group LLC set a $34.00 target price on Akorn and gave the stock a “hold” rating in a research note on Sunday, October 29th. Zacks Investment Research raised Akorn from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 24th. Piper Jaffray Companies set a $34.00 target price on Akorn and gave the stock a “hold” rating in a research note on Sunday, October 22nd. Finally, Royal Bank Of Canada reissued a “hold” rating and issued a $34.00 target price on shares of Akorn in a research note on Tuesday, October 3rd. Three investment analysts have rated the stock with a sell rating, nine have given a hold rating and one has given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $29.38.

A number of institutional investors have recently bought and sold shares of AKRX. Teachers Advisors LLC boosted its position in Akorn by 1.8% during the 1st quarter. Teachers Advisors LLC now owns 155,688 shares of the company’s stock valued at $3,749,000 after acquiring an additional 2,727 shares in the last quarter. Legal & General Group Plc boosted its position in Akorn by 113.4% during the 1st quarter. Legal & General Group Plc now owns 55,381 shares of the company’s stock valued at $1,334,000 after acquiring an additional 29,429 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in Akorn by 3.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,142,067 shares of the company’s stock valued at $27,501,000 after acquiring an additional 37,537 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its position in Akorn by 21.4% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 315,901 shares of the company’s stock valued at $7,607,000 after acquiring an additional 55,746 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund boosted its position in Akorn by 4.3% during the 2nd quarter. Oregon Public Employees Retirement Fund now owns 32,085 shares of the company’s stock valued at $1,076,000 after acquiring an additional 1,329 shares in the last quarter. 74.66% of the stock is currently owned by institutional investors and hedge funds.

About Akorn

Akorn Inc (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health.

Receive News & Ratings for Akorn Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn Inc. and related companies with MarketBeat.com's FREE daily email newsletter.